Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Seven factors were associated with ICAS, as suggested by the meta-analysis, including advanced age (odds ratio (OR) 1.05, 95% CI 1.03-1.08), metabolic syndrome (OR 2.13, 95% CI 1.35-3.37), diabetes mellitus (OR 1.98, 95% CI 1.69-2.31), hypertension (OR 1.97, 95% CI 1.69-2.31), dyslipidemia (OR 1.29, 95% CI 1.04-1.59), high levels of low-density lipoprotein cholesterol (OR 1.06, 95% CI 1.00-1.12) and high levels of apolipoprotein A1 (OR 0.34, 95% CI 0.15-0.75).
|
30658194 |
2019 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Those with remission of hypertension had a significant weight loss (p < 0.001), decrease in body mass index (p < 0.001), 24-h total systolic BP (p = 0.047), baPWV (p = 0.042), triglycerides (p = 0.049) and apolipoprotein B/apolipoprotein A1 (p = 0.004), and an increase in high-density lipoprotein cholesterol (p < 0.001) at 1 year.
|
30317431 |
2019 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Eight correlations between clinical and epidemiological data and protein expression were noteworthy: diabetes mellitus vs. Ig gamma-2 and apolipoprotein-A1 and albumin; congestive heart failure vs. Ig lambda-2; colonization vs. actin; compressive therapy vs. Ig kappa; systemic arterial hypertension vs. alpha-2-macroglobulin and apolipoprotein-A1; area of ulcer vs. apolipoprotein-A1; race vs. heavy chain Ig and Ig γ-1 chain; age and race vs. Ig γ-1 chain.
|
30261322 |
2019 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein (apo) B, apolipoprotein A-I (apoA-I), LDL particle and HDL particle concentrations were all decreased in PA subjects vs control subjects and subjects with untreated hypertension (P < 0.016).
|
30372543 |
2019 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Baseline urinary Hcy-thiolactone/creatinine was significantly associated with plasma tHcy, ApoA1, glomerular filtration rate, potassium and pyridoxal 5'-phosphate (positively) and with age, hypertension, smoking, urinary creatinine, plasma bilirubin and kynurenine (negatively).
|
30193001 |
2019 |
Amyloidosis, familial visceral
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
A novel APOA1 mutation in a patient with renal amyloidosis: unveiling amyloid by next-generation sequencing.
|
31482740 |
2019 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
HDL-C (for PVWMLs: OR 0.36, 95% CI 0.19-0.71; for DWMLs: OR 0.35, 95% CI 0.20-0.63) and apoA-1 (for PVWMLs: OR 0.27, 95% CI 0.11-0.66; for DWMLs: OR 0.22, 95% CI 0.10-0.48) were inversely associated with the severity of PVWMLs and DWMLs in women but not in men after adjustment for age, hypertension, diabetes, current smoking, daily drinking, body mass index and uric acid.
|
29162363 |
2018 |
Amyloidosis, familial visceral
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
A case report of hereditary apolipoprotein A-I amyloidosis associated with a novel APOA1 mutation and variable phenotype.
|
27240838 |
2016 |
Amyloidosis, familial visceral
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Advantages and pitfalls of an extended gene panel for investigating complex neurometabolic phenotypes.
|
27604308 |
2016 |
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
This study investigated the relationship between the MTHFR polymorphism and hypertension and correlated blood lipid indexes, including homocysteine (HCY), lipoprotein (a) [Lp (a)], high-density lipoprotein (HDL), low-density lipoprotein (LDL), apolipoprotein A I (Apo AI), Apo B, glucose (GLU), total cholesterol (TC), and triglyceride (TG), in a Chinese population.
|
25489783 |
2015 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p.
|
24963038 |
2014 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
The HTN-induced increase in leukocyte and platelet adhesion was attenuated in apolipoprotein A-I transgenic mice (ApoA1-Tg) and blunted in wild-type mice treated with the ApoA1 mimetic peptide, 4F.
|
23281427 |
2013 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
RGD |
High blood pressure effects on the blood to cerebrospinal fluid barrier and cerebrospinal fluid protein composition: a two-dimensional electrophoresis study in spontaneously hypertensive rats.
|
23401751 |
2013 |
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
APOA1 polymorphisms analysis may be a useful tool to identify risk factors for subjects and families and clarify the physiopathological role of these polymorphisms in age-related diseases, such as hypertension and obesity.
|
19408098 |
2009 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
CTD_human |
Simvastatin reverses the hypertension of heterozygous mice lacking cystathionine beta-synthase and apolipoprotein A-I.
|
18224302 |
2008 |
Amyloidosis, familial visceral
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Organ transplantation in hereditary apolipoprotein AI amyloidosis.
|
16925563 |
2006 |
Hypertensive disease
|
0.700 |
AlteredExpression
|
group |
BEFREE |
The presence of CAD was associated with current, past or passive smoking, a history of diabetes and high blood pressure, a positive family risk factors in this study; levels were below history of CAD, body fat percentage, waist-hip ratio (WHR), low apolipoprotein A1 or low HDL, lipoprotein (a), glucose, insulin, insulin resistance, C-reactive protein (CRP), total cholesterol to HDL ratio (TC/HDL) and creatinine on univariate conditional logistic regression analysis.
|
14741073 |
2004 |
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
LHGDN |
Apolipoprotein AI promoter variant in blood pressure determination.
|
12030900 |
2002 |
Amyloidosis, familial visceral
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Familial nephropathic systemic amyloidosis caused by apolipoprotein AI variant Arg26.
|
8208902 |
1994 |
Amyloidosis, familial visceral
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis.
|
1502149 |
1992 |
Amyloidosis, familial visceral
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy.
|
2123470 |
1990 |
Amyloidosis, familial visceral
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Variant apolipoprotein AI as a major constituent of a human hereditary amyloid.
|
3142462 |
1988 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
HPO |
|
|
|
Amyloidosis, familial visceral
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Amyloidosis, familial visceral
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|